ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 9,520 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 9,520 shares of the stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $65.40, for a total transaction of $622,608.00. Following the completion of the sale, the chief operating officer now owns 809,852 shares in the company, valued at $52,964,320.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Muthusamy Shanmugam also recently made the following trade(s):

• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $66.33, for a total transaction of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total transaction of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $55.95, for a total value of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total value of $541,055.20.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $65.48 on Thursday. The firm’s 50 day moving average is $64.60 and its 200-day moving average is $58.52. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $1.38 billion, a PE ratio of 77.95 and a beta of 0.79. ANI Pharmaceuticals, Inc. has a 12-month low of $36.99 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The firm had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANIP. Truist Financial boosted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. HC Wainwright boosted their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Finally, Capital One Financial started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $80.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 248 shares in the last quarter. BluePath Capital Management LLC bought a new stake in ANI Pharmaceuticals during the third quarter worth $34,000. Pacer Advisors Inc. acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at $41,000. Point72 Asset Management L.P. lifted its stake in ANI Pharmaceuticals by 60.0% in the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 291 shares during the last quarter. Finally, Coppell Advisory Solutions LLC bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $44,000. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.